These neuropeptides are key regulators of social behavior in mammals, and targeted disruption of these pathways induces social deficits in multiple species. 4 These collective findings suggest that disturbances in brain OXT and/or AVP signaling may be related to the presence and severity of social impairments in people with autism. Evaluating a role for these brain neuropeptides in autism has been hindered, however, by the extraordinary difficulty in obtaining brain-relevant samples (eg, cerebrospinal fluid [CSF] ) from children for research purposes. Here, we surmount this challenge by assembling the largest autism cohort to date in which to evaluate CSF neuropeptide concentrations. We first tested whether children with and without autism show different CSF neuropeptide concentrations at a group level. We then tested whether CSF neuropeptide concentration distinguishes individual autism cases from controls and predicts individual symptom severity for core autism features, particularly social impairments. We also explored whether there is evidence for sex-specific autism disease biology (as AVP may more selectively regulate social functioning in male mammals, whereas OXT may more selectively regulate social functioning in female mammals 5 ).
Subjects and Methods

Participants
Study protocols were approved by institutional review boards ( 12 Control children were required to be diagnosed with or worked up for a medical problem (other than autism) that necessitated lumbar puncture. All participants were free of severe mental disorders (eg, schizophrenia, schizoaffective disorder, bipolar disorder) as determined by an extensive neurological evaluation in children with autism and by a medical chart review in control children.
CSF Collection, Case-Control Matching, and Neuropeptide Quantification CSF was collected from the lumbar region, flash-frozen, and stored at −80 C until quantification. Children with autism who had sufficient available CSF sample volumes from the NIMH site were matched with control children from the Stanford and UCSF sites 1:1 on sex and within a 1-year band on age (age range = 1.5-9 years; combined cohort, N = 72; see Tables 1 and  2 for participant characteristics). CSF AVP and OXT concentrations were quantified at Stanford University using enzyme immunoassays (Enzo Life Sciences, Farmingdale, NY). 6 
Statistical Analyses
Data were analyzed using JMP Pro 13 and SAS 9.4. We used least-squares general linear models (LS-GLM) to test for group differences in CSF AVP and/or OXT concentrations. We used logistic regression models, implemented as restricted maximum likelihood generalized linear models, to test whether CSF AVP and/or OXT concentrations accurately differentiated cases from controls at an individual (rather than group) level. A post hoc contrast was used to perform an equivalence test to confirm that we were sufficiently powered to detect a meaningful effect size in OXT concentrations. Finally, we used LS-GLM to test whether CSF AVP and/or OXT concentrations predicted individual symptom severity in the autism group. We first examined overall symptom severity using the ADOS-Calibrated Severity Score (CSS) 13 ; secondary analyses were then conducted on the Social Affect (SA)-CSS and the Restricted and Repetitive Behaviors (RRB)-CSS, with critical alpha set at 0.025 to account for multiple testing within this instrument. Participant age, CSF sample collection time, ethnicity, and sex were included as control variables in all models. Interaction terms were included and then removed when nonsignificant, following best practice. 14 To meet the underlying assumptions of the analytical methods, 14, 15 homogeneity of variance, normality of error, and linearity were confirmed post hoc 14 and CSF AVP and OXT concentrations were log-transformed in all analyses.
Results
Mean CSF AVP concentration was significantly lower in the autism versus control group (F 1, 66 = 14.20, At an individual level, CSF AVP concentration also significantly differentiated cases from controls (likelihood ratio [LR] chi-square = 15.14, p < 0.0001). This relationship was observed in both males and females, as there was no evidence for a CSF AVP concentration-by-sex interaction (LR = 0.7279, p = 0.3936). This effect was also specific to AVP, as CSF OXT concentration did not predict autism likelihood in these same individuals (LR = 0.5200, p = 0.4710). An equivalence test showed that the effect size for CSF OXT concentration was significantly lower than that for CSF AVP concentration (LR = 6.93, p = 0.0085; ie, there was sufficient power to detect a biologically meaningful effect size for CSF OXT in this study).
At an individual level, CSF AVP concentration significantly predicted overall symptom severity in a sex-dependent manner (F 1, 27 = 4.878, p = 0.0359), whereby lower CSF AVP concentration predicted greater symptom severity in males (F 1, 27 = 6.221, p = 0.0190, β 1,1 ± SE = −5.091 ± 2.041), but not in females (F 1, 27 = 0.2346, p = 0.6320, β 1,2 ± SE = 0.9526 ± 0.1.967), as measured by the ADOS-CSS. Further investigation revealed that this effect was specific to the social domain (F 1, 27 = 7.708, p = 0.0099), whereby lower CSF AVP concentration predicted greater social impairments as measured by higher SA-CSS in males (F 1, 27 = 8.771, p = 0.0063, β 1,1 ± SE = −5.604 ± 1.892) but not in females (F 1, 27 = 0.6229, p = 0.4369, β 1,2 ± SE = −1.439 ± 1.823; see Fig 1) . In contrast, CSF AVP concentration did not predict severity scores for RRB-CSS (F 1, 27 = 0.0274, p = 0.8698). Finally, no effect of CSF OXT concentration on any ADOS measure was found (p > 0.05 for all tests). Fisher exact test was used to test whether the distribution of individuals to different groups differed by sex and ethnicity. For age and blood collection time, differences between groups were tested using a simple 1-way general linear model (values are reported as mean ± standard error). No significant differences were observed between children with autism and control children. CSF = cerebrospinal fluid.
Discussion
This study implicated CSF AVP concentration in disease presence and symptom severity in children with autism.
To date, autism biomarker research has been largely restricted to peripheral tissue, such as blood, due to its ease in collection. However, these measures are less representative of brain biochemistry than CSF. We observed no difference in blood AVP concentrations between children with and without autism in a prior study. 9 Results of the present investigation highlight the value of performing CSF-focused biomarker research in autism, and parallel ongoing research in other brain disorders (ie, dementia, multiple sclerosis), which have benefited tremendously from CSF biomarker discovery efforts. 16, 17 Although AVP and OXT are nearly structurally identical peptides and likely evolved due to duplication of a common ancestral gene, 18 only CSF AVP concentration was identified as a driver of group classification. Additionally, the relationship between CSF AVP concentration and symptom severity was only evident in males. A unique aspect of AVP physiology that may explain these results is that AVP can exert sexually dimorphic behavioral effects. 5 Specifically, AVP preferentially regulates mating behavior, pair bond formation, and parental care in male versus female mammals. 19 Given autism's male-biased prevalence, 2 brain AVP signaling deficits may be particularly relevant to understanding the male-biased risk for, and symptom presentation in, autism. These biomarker findings are also of interest because there are currently no laboratory-based diagnostic tests to detect autism. However, the accuracy of low CSF AVP concentration to correctly identify autism cases in this study, although robust, was imperfect, as n = 8 children with autism (5 male, 3 female) and n = 9 control children (7 male, 2 female) were misclassified by the analysis.
Given that autism is a clinically heterogeneous disorder and that CSF AVP concentration did not predict RRB-CSS in children with autism, it is likely that other as yet unidentified CSF biomarkers may contribute additional explanatory power and could be incorporated into a multidimensional panel by which to detect autism with even higher accuracy.
There has been intense interest in OXT as a therapeutic agent for autism. Although the present CSF study does not support a global need for OXT "replacement" in this disorder (if anything, it supports one for AVP), it is nevertheless possible that a subset of people with autism may benefit from OXT treatment. Rodent models of human syndromes with high autism penetrance 20, 21 have implicated diminished hypothalamic OXT-producing cell numbers in the models' social deficits, which can be rescued with OXT treatment. 20, 22 We have also previously
shown that idiopathic autism patients with the lowest blood OXT concentrations benefit the most from OXT treatment. 23 These collective findings underscore the complexity in detecting and treating idiopathic and syndromic forms of autism, and the urgent need for biomarkerstratified neuropeptide treatment trials in this highly heterogeneous patient population. There are several limitations to this study. First, the control group was a sample of convenience due to ethical concern in obtaining CSF from children solely for research purposes. Moreover, although the controls did not have autism, they had either unknown conditions necessitating CSF analysis (eg, severe headache, unexplained changes in mental status, rule-out meningitis) or serious medical conditions (eg, pseudotumor cerebri, survivors of blood cancers on maintenance chemotherapy). Evaluation of CSF AVP concentrations in infants at familial risk for autism (some of whom would develop typically), and in adults Total Calibrated Severity Score 7 4-10 a Nonverbal developmental quotient (ratio of age equivalents to chronological age) was calculated for nonverbal cognitive ability, from either the Mullen Scales of Early Learning or the Differential Ability Scales, based on age and ability level. ADOS = Autism Diagnostic Observation Schedule; SD = standard deviation.
with autism (age-matched to controls capable of consenting to CSF collection), would enable comparison with healthy participants. Second, given the extreme difficulty in obtaining CSF samples from children, control CSF was collected at Stanford and UCSF hospitals across multiple services and clinics. In contrast, autism CSF was collected in a more structured manner at NIMH. Accordingly, there were differences in clinical sampling conditions: fasting status, fluid replacement, and anesthesia (general vs local) were variable across controls, whereas children with autism were required to be fasted and then underwent general anesthesia and fluid replacement before lumbar puncture. The impact of these differences on the neuropeptide measures is unknown. It seems unlikely that these methodologic differences are responsible for the observed differences in patient groups, however, as we recently observed significantly lower CSF AVP concentrations in socially impaired versus socially competent monkeys undergoing identical CSF collection procedures, and in a small pilot study in which children with autism were not necessarily fasted and did not undergo pre-lumbar puncture fluid replacement. 6 In conclusion, this study showed that CSF AVP concentration differentiates cases from controls and is associated with symptom severity in children with autism. Additional research is needed to determine whether low CSF AVP concentration is specific to autism (as opposed to a more general "signature" of altered brain development), and whether low CSF AVP concentration is a disease marker in children at risk for developing autism prior to symptom onset. Given that there is longstanding evidence that AVP administration enhances social functioning in mammals, 24 therapeutic enhancement of brain AVP signaling may also hold promise for ameliorating social deficits in autism patients. 
